CVRx, Inc. (CVRX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$1.47-6.96%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · CVRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -81.8% |
| Our one-year growth estimate | diamond | 5.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 87.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 43 industry peers
CVRX — CFO transition
Dated 2026-09-21
CFO — John Landry: The filing announces the appointment of an external CFO to succeed a previously disclosed resigning officer, representing an orderly succession rather than a sudden loss of leadership.
Why it matters: The trial could open Barostim to about three times as many patients. Enrollment progress is the next clear sign of whether this path is moving.
Supportive ifCVRx reports more patients enrolled in BENEFIT-HF and keeps the trial on its stated path.
Worry ifCVRx reports enrollment delays, a paused trial, or a change that narrows the planned patient group.
Why it matters: CVRx cut its 2026 revenue range from $63 million–$67 million to $58 million–$60 million. Results below the new low end would show more pressure than its revised plan.
Worry ifCVRx reports 2026 revenue below $58 million.
Less concerning ifCVRx reports 2026 revenue of at least $58 million.
Why it matters: Humana began covering Barostim for some Medicare Advantage patients in May. More coverage could help clinics treat more patients.
Supportive ifCVRx reports more Barostim use linked to Humana coverage. Or it names another large payer with a new coverage policy.
Worry ifCVRx reports that Humana coverage has not eased payer access or that payer delays still limit sales.
Why it matters: The sales leader left after CVRx lowered its outlook and cited weak sales execution. A permanent hire would mark progress in fixing that gap.
Supportive ifCVRx names a permanent sales head and gives a start date.
Worry ifCVRx has not named a permanent sales head by its next quarterly report, or reports further sales team gaps.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$289 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $872 loss on $10,000 · 8.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,706 loss on $10,000 · 87.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: CVRx set Q3 revenue guidance at $13.5 million to $14.5 million. A result below the low end would deepen concern about slower sales.
Worry ifOn the November 5 earnings report, Q3 revenue is below $13.5 million.
Less concerning ifOn the November 5 earnings report, Q3 revenue is at least $13.5 million.